Kristoffer Hellstrand

Professor

University of Gothenburg

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Kristoffer Hellstrand is a Professor at the University of Gothenburg in Sweden. His research encompasses immunotherapy efficacy, particularly in the context of acute myeloid leukemia, COVID-19, and multiple sclerosis. He has authored recent articles focusing on immune responses and treatment outcomes in these critical health areas, contributing significantly to the field of immunology.

Articles (8)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (4)

Martin Lagging

Professor in Clinical Virology

Göteborgs Universitet

SWEDEN

View details

Anna Martner

Professor

University of Gothenburg

SWEDEN

View details

Johan Ringlander

University of Gothenburg

SWEDEN

View details

Fredrik B Thorén

Professor

University of Gothenburg

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kristoffer Hellstrand

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia

Catch-up antibody responses and hybrid immunity in mRNA vaccinated patients at risk of severe COVID-19

Transient and durable T cell reactivity after COVID-19

Impact of CYBA genotypes on severity and progression of multiple sclerosis

Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus

Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance

Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Collaborators (4)

Martin Lagging

Anna Martner

Johan Ringlander

Fredrik B Thorén

Make your next move.